Clinical bottom line
Novel biologic therapies targeting type 2 inflammation pathways have demonstrated significant efficacy in managing chronic rhinosinusitis with nasal polyps (CRSwNP), including in patients with autoimmune comorbidities. Agents such as dupilumab reduce polyp size, improve nasal obstruction, and enhance quality of life. However, patient response varies, and optimal integration with surgery and conventional treatments requires individualized approaches. Biomarkers like periostin may help predict therapeutic outcomes, but further validation is needed.
What the evidence shows
CRSwNP is a chronic inflammatory condition often driven by type 2 cytokines (IL-4, IL-5, IL-13), with overlapping immune dysregulation in autoimmune diseases (Park et al., 2014). Biologics targeting these pathways have emerged as effective options, especially for refractory cases.
Bachert et al. (2022) provide a comprehensive review of biologics in CRSwNP, highlighting dupilumab’s efficacy in reducing polyp burden and improving sinonasal symptoms. Dupilumab’s dual blockade of IL-4 and IL-13 pathways addresses key inflammatory drivers.
Takaishi et al. (2026) identify clinical and biomarker factors associated with dupilumab response, noting that higher baseline eosinophil counts and periostin levels correlate with better outcomes. These findings suggest potential for biomarker-guided therapy in autoimmune patients with CRSwNP.
De Corso et al. (2026) report consensus recommendations from EUFOREA/EPOS endorsing biologics as adjuncts or alternatives to surgery in selected patients, emphasizing multidisciplinary evaluation. They advocate personalized treatment plans integrating biologics, surgery, and corticosteroids.
AW Michael et al. (2023) discuss advances in biologic therapies, including emerging agents targeting IL-5 and IgE, expanding therapeutic options. Their review underscores the importance of tailoring therapy to endotypes and comorbidities.
Cordeiro et al. (2018) explore periostin’s role in aspirin-exacerbated respiratory disease, a CRSwNP subtype with autoimmune features, reinforcing periostin as a biomarker and potential therapeutic target.
Exhaled and nasal nitric oxide measurements provide noninvasive markers of airway inflammation and may assist in monitoring disease activity and response to therapy (Rhinology journal, 2017).
Verapamil’s role remains uncertain; a recent systematic review (2025) found insufficient evidence to support its use in CRSwNP.
Caveats and uncertainty
Most biologic trials have limited data specifically in autoimmune populations; extrapolation warrants caution.
Long-term safety and cost-effectiveness of biologics require further study.
Biomarker thresholds for predicting response are not yet standardized.
Optimal timing and sequencing of biologics relative to surgery remain to be defined.
Heterogeneity in CRSwNP phenotypes and autoimmune comorbidities complicates treatment algorithms.
How this may change practice
Clinicians should consider biologics, particularly dupilumab, for autoimmune patients with refractory CRSwNP, especially those with type 2 inflammatory features.
Biomarker assessment (e.g., eosinophils, periostin) may guide patient selection and predict response.
Multidisciplinary collaboration among immunologists, otolaryngologists, and allergists is essential for integrated care.
Biologics may reduce the need for repeated surgery and systemic corticosteroids, improving patient outcomes.
Ongoing monitoring and individualized treatment adjustments are critical to optimize efficacy and safety.